[1] Chiti, F.; Dobson, C. M., Protein misfolding, functional amyloid, and human disease. Annu. Rev. Biochem. 2006, 75, 333-66.
[2] Chiti, F.; Dobson, C. M., Protein Misfolding, Amyloid Formation, and Human Disease: A Summary of Progress Over the Last Decade. Annu. Rev. Biochem. 2017, 86, 27-68.
[3] Sipe, J. D.; Benson, M. D.; Buxbaum, J. N.; Ikeda, S.; Merlini, G.; Saraiva, M. J.; Westermark, P., Nomenclature 2014: Amyloid fibril proteins and clinical classification of the amyloidosis. Amyloid 2014, 21 (4), 221-4.
[4] Sipe, J. D.; Benson, M. D.; Buxbaum, J. N.; Ikeda, S.; Merlini, G.; Saraiva, M. J.; Westermark, P.; Nomenclature Committee of the International Society of, A., Amyloid fibril protein nomenclature: 2012 recommendations from the Nomenclature Committee of the International Society of Amyloidosis. Amyloid 2012, 19 (4), 167-70.
[5] Westermark, P.; Andersson, A.; Westermark, G. T., Islet amyloid polypeptide, islet amyloid, and diabetes mellitus. Physiol. Rev. 2011, 91 (3), 795-826.
[6] Spillantini, M. G.; Schmidt, M. L.; Lee, V. M.; Trojanowski, J. Q.; Jakes, R.; Goedert, M., Alpha-synuclein in Lewy bodies. Nature 1997, 388 (6645), 839-40.
[7] Goedert, M., NEURODEGENERATION. Alzheimer's and Parkinson's diseases: The prion concept in relation to assembled Abeta, tau, and alpha-synuclein. Science 2015, 349 (6248), 1255555.
[8] Martin, L.; Latypova, X.; Terro, F., Post-translational modifications of tau protein: implications for Alzheimer's disease. Neurochem. Int. 2011, 58 (4), 458-71.
[9] Selkoe, D. J.; Hardy, J., The amyloid hypothesis of Alzheimer's disease at 25 years. EMBO Mol. Med. 2016, 8 (6), 595-608.
[10] Kayed, R.; Head, E.; Thompson, J. L.; McIntire, T. M.; Milton, S. C.; Cotman, C. W.; Glabe, C. G., Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 2003, 300 (5618), 486-9.
[11] Thibaudeau, T. A.; Anderson, R. T.; Smith, D. M., A common mechanism of proteasome impairment by neurodegenerative disease-associated oligomers. Nat. Commun. 2018, 9 (1), 1097.
[12] Cheignon, C.; Tomas, M.; Bonnefont-Rousselot, D.; Faller, P.; Hureau, C.; Collin, F., Oxidative stress and the amyloid beta peptide in Alzheimer's disease. Redox Biol. 2018, 14, 450-464.
[13] Fossati, S.; Giannoni, P.; Solesio, M. E.; Cocklin, S. L.; Cabrera, E.; Ghiso, J.; Rostagno, A., The carbonic anhydrase inhibitor methazolamide prevents amyloid beta-induced mitochondrial dysfunction and caspase activation protecting neuronal and glial cells in vitro and in the mouse brain. Neurobiol. Dis. 2016, 86, 29-40.
[14] Tyedmers, J.; Mogk, A.; Bukau, B., Cellular strategies for controlling protein aggregation. Nat. Rev. Mol. Cell Biol. 2010, 11 (11), 777-88.
[15] Dobson, C. M., Protein folding and misfolding. Nature 2003, 426 (6968), 884-90.
[16] Petkova, A. T.; Ishii, Y.; Balbach, J. J.; Antzutkin, O. N.; Leapman, R. D.; Delaglio, F.; Tycko, R., A structural model for Alzheimer's beta -amyloid fibrils based on experimental constraints from solid state NMR. Proc. Natl. Acad. Sci. U. S. A. 2002, 99 (26), 16742-7.
[17] Luca, S.; Yau, W. M.; Leapman, R.; Tycko, R., Peptide conformation and supramolecular organization in amylin fibrils: constraints from solid-state NMR. Biochemistry 2007, 46 (47), 13505-22.
[18] van der Wel, P. C.; Lewandowski, J. R.; Griffin, R. G., Solid-state NMR study of amyloid nanocrystals and fibrils formed by the peptide GNNQQNY from yeast prion protein Sup35p. J. Am. Chem. Soc. 2007, 129 (16), 5117-30.
[19] Nelson, R.; Sawaya, M. R.; Balbirnie, M.; Madsen, A. O.; Riekel, C.; Grothe, R.; Eisenberg, D., Structure of the cross-beta spine of amyloid-like fibrils. Nature 2005, 435 (7043), 773-8.
[20] Petkova, A. T.; Ishii, Y.; Balbach, J. J.; Antzutkin, O. N.; Leapman, R. D.; Delaglio, F.; Tycko, R., A structural model for Alzheimer's beta -amyloid fibrils based on experimental constraints from solid state NMR. Proc. Natl. Acad. Sci. U. S. A. 2002, 99 (26), 16742-7.
[21] Nguyen, H. D.; Hall, C. K., Molecular dynamics simulations of spontaneous fibril formation by random-coil peptides. Proc. Natl. Acad. Sci. U. S. A. 2004, 101 (46), 16180-5.
[22] Sugita, Y.; Okamoto, Y. J. C. p. l., Replica-exchange molecular dynamics method for protein folding. 1999, 314 (1-2), 141-151.
[23] Xue, W. F.; Homans, S. W.; Radford, S. E., Systematic analysis of nucleation-dependent polymerization reveals new insights into the mechanism of amyloid self-assembly. Proc. Natl. Acad. Sci. U. S. A. 2008, 105 (26), 8926-31.
[24] Pryor, N. E.; Moss, M. A.; Hestekin, C. N., Unraveling the early events of amyloid-beta protein (Abeta) aggregation: techniques for the determination of Abeta aggregate size. Int. J. Mol. Sci. 2012, 13 (3), 3038-72.
[25] Biancalana, M.; Koide, S., Molecular mechanism of Thioflavin-T binding to amyloid fibrils. Biochim Biophys Acta 2010, 1804 (7), 1405-12.
[26] Kumar, S.; Walter, J., Phosphorylation of amyloid beta (Abeta) peptides - a trigger for formation of toxic aggregates in Alzheimer's disease. Aging (Albany NY) 2011, 3 (8), 803-12.
[27] Maji, S. K.; Wang, L.; Greenwald, J.; Riek, R., Structure-activity relationship of amyloid fibrils. FEBS Lett 2009, 583 (16), 2610-7.
[28] Serrano-Pozo, A.; Frosch, M. P.; Masliah, E.; Hyman, B. T., Neuropathological alterations in Alzheimer disease. Cold Spring Harb Perspect Med. 2011, 1 (1), a006189.
[29] Zafeiris, D.; Rutella, S.; Ball, G. R., An Artificial Neural Network Integrated Pipeline for Biomarker Discovery Using Alzheimer's Disease as a Case Study. Comput. Struct. Biotechnol. J. 2018, 16, 77-87.
[30] Selkoe, D. J., Cell biology of the beta-amyloid precursor protein and the genetics of Alzheimer's disease. Cold Spring Harb Symp Quant Biol. 1996, 61, 587-96.
[31] Olsson, F.; Schmidt, S.; Althoff, V.; Munter, L. M.; Jin, S.; Rosqvist, S.; Lendahl, U.; Multhaup, G.; Lundkvist, J., Characterization of intermediate steps in amyloid beta (Abeta) production under near-native conditions. J. Biol. Chem. 2014, 289 (3), 1540-50.
[32] Thathiah, A.; De Strooper, B., The role of G protein-coupled receptors in the pathology of Alzheimer's disease. Nat. Rev. Neurosci. 2011, 12 (2), 73-87.
[33] Mucke, L.; Selkoe, D. J., Neurotoxicity of amyloid beta-protein: synaptic and network dysfunction. Cold Spring Harb Perspect Med. 2012, 2 (7), a006338.
[34] Yoshiike, Y.; Chui, D. H.; Akagi, T.; Tanaka, N.; Takashima, A., Specific compositions of amyloid-beta peptides as the determinant of toxic beta-aggregation. J. Biol. Chem. 2003, 278 (26), 23648-55.
[35] Luo, X.; Yan, R., Inhibition of BACE1 for therapeutic use in Alzheimer's disease. Int. J. Clin. Exp. Pathol 2010, 3 (6), 618-28.
[36] Morgan, D., Immunotherapy for Alzheimer's disease. J. Intern. Med. 2011, 269 (1), 54-63.
[37] Zhang, C., Natural compounds that modulate BACE1-processing of amyloid-beta precursor protein in Alzheimer's disease. Discov. Med. 2012, 14 (76), 189-97.
[38] Ribet, D.; Cossart, P., Post-translational modifications in host cells during bacterial infection. FEBS Lett. 2010, 584 (13), 2748-58.
[39] Song, L.; Xue, R.; Ge, P.; Li, M.; Wang, L.; Zheng, F.; Zhao, L.; Wang, Z.; Wang, Z.; Wang, Q.; Liu, N.; Sun, X., Identification of post-translational modifications of Abeta peptide in platelet membranes from patients with cerebral amyloid angiopathy. J. Neurol. Sci. 2017, 383, 11-17.
[40] Iannuzzi, C.; Irace, G.; Sirangelo, I., Differential effects of glycation on protein aggregation and amyloid formation. Front. Mol. Biosci. 2014, 1, 9.
[41] Ulrich, P.; Cerami, A., Protein glycation, diabetes, and aging. Recent Prog. Horm. Res. 2001, 56, 1-21.
[42] Ahmed, N., Advanced glycation endproducts-role in pathology of diabetic complications. Diabetes Res. Clin. Pract. 2005, 67 (1), 3-21.
[43] Delgado-Andrade, C., Carboxymethyl-lysine: thirty years of investigation in the field of AGE formation. Food Funct. 2016, 7 (1), 46-57.
[44] Reddy, S.; Bichler, J.; Wells-Knecht, K. J.; Thorpe, S. R.; Baynes, J. W., N epsilon-(carboxymethyl)lysine is a dominant advanced glycation end product (AGE) antigen in tissue proteins. Biochemistry 1995, 34 (34), 10872-8.
[45] Singh, V. P.; Bali, A.; Singh, N.; Jaggi, A. S., Advanced glycation end products and diabetic complications. Korean J. Physiol. Pharmacol. 2014, 18 (1), 1-14.
[46] Grillo, M. A.; Colombatto, S., Advanced glycation end-products (AGEs): involvement in aging and in neurodegenerative diseases. Amino Acids 2008, 35 (1), 29-36.
[47] Castellani, R. J.; Harris, P. L.; Sayre, L. M.; Fujii, J.; Taniguchi, N.; Vitek, M. P.; Founds, H.; Atwood, C. S.; Perry, G.; Smith, M. A., Active glycation in neurofibrillary pathology of Alzheimer disease: N(epsilon)-(carboxymethyl) lysine and hexitol-lysine. Free Radic Biol. Med. 2001, 31 (2), 175-80.
[48] Sasaki, N.; Fukatsu, R.; Tsuzuki, K.; Hayashi, Y.; Yoshida, T.; Fujii, N.; Koike, T.; Wakayama, I.; Yanagihara, R.; Garruto, R.; Amano, N.; Makita, Z., Advanced glycation end products in Alzheimer's disease and other neurodegenerative diseases. Am. J. Pathol. 1998, 153 (4), 1149-55.
[49] Vitek, M. P.; Bhattacharya, K.; Glendening, J. M.; Stopa, E.; Vlassara, H.; Bucala, R.; Manogue, K.; Cerami, A., Advanced glycation end products contribute to amyloidosis in Alzheimer disease. Proc. Natl. Acad. Sci. U. S. A. 1994, 91 (11), 4766-70.
[50] Chen, K.; Maley, J.; Yu, P. H., Potential inplications of endogenous aldehydes in beta-amyloid misfolding, oligomerization and fibrillogenesis. J. Neurochem. 2006, 99 (5), 1413-24.
[51] Jana, A. K.; Batkulwar, K. B.; Kulkarni, M. J.; Sengupta, N., Glycation induces conformational changes in the amyloid-beta peptide and enhances its aggregation propensity: molecular insights. Phys. Chem. Chem. Phys. 2016, 18 (46), 31446-31458.
[52] Li, X. H.; Du, L. L.; Cheng, X. S.; Jiang, X.; Zhang, Y.; Lv, B. L.; Liu, R.; Wang, J. Z.; Zhou, X. W., Glycation exacerbates the neuronal toxicity of beta-amyloid. Cell Death Dis. 2013, 4, e673.
[53] Fica-Contreras, S. M.; Shuster, S. O.; Durfee, N. D.; Bowe, G. J. K.; Henning, N. J.; Hill, S. A.; Vrla, G. D.; Stillman, D. R.; Suralik, K. M.; Sandwick, R. K.; Choi, S., Glycation of Lys-16 and Arg-5 in amyloid-beta and the presence of Cu(2+) play a major role in the oxidative stress mechanism of Alzheimer's disease. J. Biol. Inorg. Chem. 2017, 22 (8), 1211-1222.
[54] Emendato, A.; Milordini, G.; Zacco, E.; Sicorello, A.; Dal Piaz, F.; Guerrini, R.; Thorogate, R.; Picone, D.; Pastore, A., Glycation affects fibril formation of Abeta peptides. J. Biol. Chem. 2018, 293 (34), 13100-13111.
[55] Ng, J.; Kaur, H.; Collier, T.; Chang, K.; Brooks, A. E. S.; Allison, J. R.; Brimble, M. A.; Hickey, A.; Birch, N. P., Site-specific glycation of Abeta1-42 affects fibril formation and is neurotoxic. J. Biol. Chem. 2019, 294 (22), 8806-8818.
[56] Lovell, M. A.; Robertson, J. D.; Teesdale, W. J.; Campbell, J. L.; Markesbery, W. R., Copper, iron and zinc in Alzheimer's disease senile plaques. J. Neurol. Sci. 1998, 158 (1), 47-52.
[57] Miller, L. M.; Wang, Q.; Telivala, T. P.; Smith, R. J.; Lanzirotti, A.; Miklossy, J., Synchrotron-based infrared and X-ray imaging shows focalized accumulation of Cu and Zn co-localized with beta-amyloid deposits in Alzheimer's disease. J. Struct. Biol. 2006, 155 (1), 30-7.
[58] Atrian-Blasco, E.; Conte-Daban, A.; Hureau, C., Mutual interference of Cu and Zn ions in Alzheimer's disease: perspectives at the molecular level. Dalton Trans 2017, 46 (38), 12750-12759.
[59] Chassaing, S.; Collin, F.; Dorlet, P.; Gout, J.; Hureau, C.; Faller, P., Copper and heme-mediated Abeta toxicity: redox chemistry, Abeta oxidations and anti-ROS compounds. Curr. Top Med. Chem. 2012, 12 (22), 2573-95.
[60] Hureau, C.; Faller, P., Abeta-mediated ROS production by Cu ions: structural insights, mechanisms and relevance to Alzheimer's disease. Biochimie. 2009, 91 (10), 1212-7.
[61] Smith, D. G.; Cappai, R.; Barnham, K. J., The redox chemistry of the Alzheimer's disease amyloid beta peptide. Biochim. Biophys. Acta. 2007, 1768 (8), 1976-90.
[62] Hureau, C.; Balland, V.; Coppel, Y.; Solari, P. L.; Fonda, E.; Faller, P., Importance of dynamical processes in the coordination chemistry and redox conversion of copper amyloid-beta complexes. J. Biol. Inorg. Chem. 2009, 14 (7), 995-1000.
[63] Shearer, J.; Szalai, V. A., The amyloid-beta peptide of Alzheimer's disease binds Cu(I) in a linear bis-his coordination environment: insight into a possible neuroprotective mechanism for the amyloid-beta peptide. J. Am. Chem. Soc. 2008, 130 (52), 17826-35.
[64] Huang, X.; Atwood, C. S.; Hartshorn, M. A.; Multhaup, G.; Goldstein, L. E.; Scarpa, R. C.; Cuajungco, M. P.; Gray, D. N.; Lim, J.; Moir, R. D.; Tanzi, R. E.; Bush, A. I., The A beta peptide of Alzheimer's disease directly produces hydrogen peroxide through metal ion reduction. Biochemistry 1999, 38 (24), 7609-16.
[65] Borghesani, V.; Alies, B.; Hureau, C., Cu(II) binding to various forms of amyloid-beta peptides. Are they friends or foes? Eur. J. Inorg. Chem. 2018, 2018 (1), 7-15.
[66] Guilloreau, L.; Combalbert, S.; Sournia-Saquet, A.; Mazarguil, H.; Faller, P., Redox chemistry of copper-amyloid-beta: the generation of hydroxyl radical in the presence of ascorbate is linked to redox-potentials and aggregation state. Chembiochem. 2007, 8 (11), 1317-25.
[67] Cheignon, C.; Jones, M.; Atrián-Blasco, E.; Kieffer, I.; Faller, P.; Collin, F.; Hureau, C., Identification of key structural features of the elusive Cu–Aβ complex that generates ROS in Alzheimer’s disease. Chemical Science 2017, 8 (7), 5107-5118.
[68] Alzheimer's Disease International. https://www.alz.co.uk/research/worldalzheimerreport2015-traditionalchinese.pdf.
[69] Mulder, C.; Verwey, N. A.; van der Flier, W. M.; Bouwman, F. H.; Kok, A.; van Elk, E. J.; Scheltens, P.; Blankenstein, M. A., Amyloid-beta(1-42), total tau, and phosphorylated tau as cerebrospinal fluid biomarkers for the diagnosis of Alzheimer disease. Clin. Chem. 2010, 56 (2), 248-53.
[70] Introduction of Alzheimer's Disease (Med). http://webcache.googleusercontent.com/search?q=cache:k6CkrcKaApsJ:jtp.taiwan-pharma.org.tw/111/099-104.html+&cd=1&hl=zh-TW&ct=clnk&gl=tw.
[71] Lukiw, W. J., Amyloid beta (Abeta) peptide modulators and other current treatment strategies for Alzheimer's disease (AD). Expert. Opin. Emerg. Drugs 2012.
[72] Choi, J. S.; Braymer, J. J.; Nanga, R. P.; Ramamoorthy, A.; Lim, M. H., Design of small molecules that target metal-A{beta} species and regulate metal-induced A{beta} aggregation and neurotoxicity. Proc. Natl. Acad. Sci. U. S. A. 2010, 107 (51), 21990-5.
[73] Pithadia, A. S.; Lim, M. H., Metal-associated amyloid-beta species in Alzheimer's disease. Curr. Opin. Chem. Biol. 2012, 16 (1-2), 67-73.
[74] Peptide synthesis. https://www.antibodies-online.com/resources/17/5034/peptide-synthesis-methods-and-reagents/.
[75] Application of Fmoc-His(Boc)-OH in Fmoc-based SPPS. http://cem.com/en/application-of-fmoc-his-boc-oh-in-fmoc-based-spps.
[76] LeVine, H., 3rd, Stopped-flow kinetics reveal multiple phases of thioflavin T binding to Alzheimer beta (1-40) amyloid fibrils. Arch. Biochem. Biophys. 1997, 342 (2), 306-16.
[77] Ban, T.; Hamada, D.; Hasegawa, K.; Naiki, H.; Goto, Y., Direct observation of amyloid fibril growth monitored by thioflavin T fluorescence. J. Biol. Chem. 2003, 278 (19), 16462-5.
[78] Wei, Y.; Thyparambil, A. A.; Latour, R. A., Protein helical structure determination using CD spectroscopy for solutions with strong background absorbance from 190 to 230nm. Biochim. Biophys. Acta. 2014, 1844 (12), 2331-7.
[79] Bitan, G., Structural study of metastable amyloidogenic protein oligomers by photo-induced cross-linking of unmodified proteins. Methods Enzymol 2006, 413, 217-36.
[80] Ghisaidoobe, A. B.; Chung, S. J., Intrinsic tryptophan fluorescence in the detection and analysis of proteins: a focus on Forster resonance energy transfer techniques. Int. J. Mol. Sci. 2014, 15 (12), 22518-38.
[81] Lakowicz, J. R., Principles of fluorescence spectroscopy. Springer Science & Business Media: 2013.
[82] Particle size Analyzer ELSZ-2000 series. http://www.otsukael.com/product/detail/productid/1/category1id/2/category2id/1/category3id/29.
[83] Manevich, Y.; Held, K. D.; Biaglow, J. E., Coumarin-3-carboxylic acid as a detector for hydroxyl radicals generated chemically and by gamma radiation. Radiat. Res. 1997, 148 (6), 580-91.